Conference
Demonstrating the value of liquid biopsy for lung cancer in a public health care system.
Abstract
3546
Background: Given the challenges of molecular profiling in patients with advanced lung cancer, this prospective study examines clinical outcomes and utility of liquid biopsy in treatment naive stage IV lung adenocarcinoma patients (Cohort 1) and in the setting of resistance to targeted therapy (Cohort 2; not reported here). Methods: This study is being conducted at 6 Canadian centres (NCT03576937) using Guardant 360 …
Authors
Juergens RA; Ezeife DA; Laskin JJ; Agulnik JS; Hao D; Laurie SA; Law JH; Le LW; Kiedrowski LA; Shepherd FA
Volume
38
Pagination
pp. 3546-3546
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2020
DOI
10.1200/jco.2020.38.15_suppl.3546
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X